Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties.
about
Synthesis, stereochemical analysis, and derivatization of myricanol provide new probes that promote autophagic tau clearance.Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation.Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbersTau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497.
P2860
Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Aminothienopyridazine inhibito ...... desirable in vivo properties.
@ast
Aminothienopyridazine inhibito ...... desirable in vivo properties.
@en
type
label
Aminothienopyridazine inhibito ...... desirable in vivo properties.
@ast
Aminothienopyridazine inhibito ...... desirable in vivo properties.
@en
prefLabel
Aminothienopyridazine inhibito ...... desirable in vivo properties.
@ast
Aminothienopyridazine inhibito ...... desirable in vivo properties.
@en
P2093
P2860
P1476
Aminothienopyridazine inhibito ...... h desirable in vivo properties
@en
P2093
Alex Crowe
Amos B Smith
Francesco Piscitelli
Gabrielle Rossidivito
John Q Trojanowski
Kurt R Brunden
Michael James
Virginia M-Y Lee
Yuemang Yao
P2860
P304
P356
10.1016/J.BMC.2012.05.027
P407
P577
2012-05-23T00:00:00Z